# Globus Medical, Inc. (GMED): Analyst Ratings Suggest a 36.28% Upside for Investors

- Link: https://www.directorstalkinterviews.com/globus-medical-inc-gmed-analyst-ratings-suggest-a-36-28-upside-for-investors/4121212499
- Published: 2025-08-18T10:38:26+01:00
- Author: Madison Wilson

Globus Medical, Inc. (NYSE: GMED), a prominent player in the healthcare sector, 
specifically within the medical devices industry, presents an intriguing opportunity
for investors. The company, with a market capitalization of $8.18 billion, has established
itself as a leader in developing and commercializing innovative healthcare solutions
for musculoskeletal disorders.

As of the latest trading data, GMED is priced at $60.57, reflecting a slight price
change of 0.55 (0.01%). This places the stock at the lower end of its 52-week range
of $51.89 to $93.32, suggesting potential room for growth. Analysts have set a target
price range of $65.00 to $106.00, with an average target price of $82.55, indicating
a potential upside of 36.28%.

A key aspect of Globus Medical’s appeal is its impressive revenue growth rate of
18.40%, a testament to its robust business operations and market demand for its 
products. The company reported an earnings per share (EPS) of 2.58, and a return
on equity (ROE) of 8.62%, highlighting its capability to generate profit from shareholders’
equity. Furthermore, with free cash flow standing at $456.1 million, Globus Medical
has substantial liquidity to invest in future growth opportunities.

Despite the absence of a trailing P/E ratio, the forward P/E is pegged at 16.76,
suggesting that the stock is reasonably valued relative to its expected earnings.
However, the lack of data on the PEG ratio, price/book, and price/sales indicates
that investors may need to consider other metrics and qualitative factors when evaluating
the stock.

Notably, Globus Medical does not offer dividends, as reflected by a payout ratio
of 0.00%. This could imply that the company is reinvesting its earnings to fuel 
further expansion rather than distributing them to shareholders.

The consensus among analysts is positive, with eight buy ratings and six hold ratings,
and no sell recommendations. This optimistic outlook aligns with the company’s strategic
advancements and innovative offerings. Globus Medical’s portfolio includes a wide
range of musculoskeletal solutions, from traditional fusion implants to cutting-
edge robotic surgery technologies like the ExcelsiusGPS platform. This diversification
not only strengthens its market position but also broadens its revenue streams.

Technical indicators provide additional insights, with a 50-day moving average of
$57.29 and a 200-day moving average of $72.52. The stock’s RSI (14) of 50.05 suggests
a neutral market sentiment, while a MACD of 1.04 above the signal line of 0.02 could
indicate a potential bullish trend.

For investors seeking exposure to the healthcare sector with a focus on innovation-
driven growth, Globus Medical offers a compelling case. Its strategic investments
in enabling technologies and comprehensive product offerings position the company
well for future success. As always, potential investors should consider their risk
tolerance and conduct thorough research before making investment decisions.

Share on:
